Protara Therapeutics, Inc. Operating Lease, Payments
Protara Therapeutics, Inc. (TARA) reported Operating Lease, Payments of $715.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-11
- Protara Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $358.00K, a 2.58% increase year-over-year.
- Protara Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $357.00K, a 7.53% increase year-over-year.
- Protara Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $357.00K, a 7.53% increase year-over-year.
- Protara Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $357.00K, a 7.53% increase year-over-year.
- Protara Therapeutics, Inc. operating lease, payments for fiscal 2025 was $1.40M, a 5.12% increase from fiscal 2024.
- Protara Therapeutics, Inc. operating lease, payments for fiscal 2024 was $1.33M, a 7.54% increase from fiscal 2023.
- Protara Therapeutics, Inc. operating lease, payments for fiscal 2023 was $1.23M, a 7.01% decline from fiscal 2022.
- Protara Therapeutics, Inc. operating lease, payments for fiscal 2022 was $1.33M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $358.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $715.00K 10-Q · filed 2026-08-11 | $1.07M derived: sum of 3 quarters · filed 2026-08-11 | $1.43M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $357.00K 10-Q · filed 2026-05-13 | $714.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.07M derived: sum of 3 quarters · filed 2026-05-13 | $1.42M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $714.00K derived: sum of 2 quarters · filed 2026-03-10 | $1.06M derived: sum of 3 quarters · filed 2026-08-11 | $1.40M 10-K · filed 2026-03-10 |
| 2025-09-30 | $357.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $706.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.04M 10-Q · filed 2025-11-10 | $1.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $349.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $681.00K 10-Q · filed 2026-08-11 | $1.01M derived: sum of 3 quarters · filed 2026-08-11 | $1.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $332.00K 10-Q · filed 2026-05-13 | $664.00K derived: sum of 2 quarters · filed 2026-05-13 | $996.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.33M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $664.00K derived: sum of 2 quarters · filed 2026-03-10 | $995.00K derived: sum of 3 quarters · filed 2026-03-10 | $1.33M 10-K · filed 2026-03-10 |
| 2024-09-30 | $332.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $663.00K derived: sum of 2 quarters · filed 2025-11-10 | $995.00K 10-Q · filed 2025-11-10 | $1.23M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $663.00K 10-Q · filed 2025-08-11 | $902.00K derived: sum of 3 quarters · filed 2025-08-11 | $1.23M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $332.00K 10-Q · filed 2025-05-08 | $571.00K derived: sum of 2 quarters · filed 2025-05-08 | $903.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.23M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $239.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $571.00K derived: sum of 2 quarters · filed 2025-03-05 | $902.00K derived: sum of 3 quarters · filed 2025-03-05 | $1.23M 10-K · filed 2025-03-05 |
| 2023-09-30 | $332.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $663.00K derived: sum of 2 quarters · filed 2024-11-12 | $995.00K 10-Q · filed 2024-11-12 | $1.33M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $663.00K 10-Q · filed 2024-08-06 | $995.00K derived: sum of 3 quarters · filed 2024-08-06 | |
| 2023-03-31 | $332.00K 10-Q · filed 2024-05-02 | $664.00K derived: sum of 2 quarters · filed 2024-05-02 | ||
| 2022-12-31 | $332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.33M 10-K · filed 2024-03-13 | ||
| 2022-09-30 | $995.00K 10-Q · filed 2023-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |